Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.
Venaxis Inc. (NASDAQ: APPY) shares gained 15.06 percent to close at $1.91 a share Monday. The stock traded between $1.68 and $1.95 on volume of 1.41 million shares traded. Analysts at Craig-Hallum have recently initiated coverage on the company with a "buy" rating and a price target of $4.00. Shares of Venaxis have fallen approximately 25.0 percent year-to-date.
Find out more about Venaxis including full access to the free equity report at:
www.RDInvesting.com/APPY
The Clorox Co. (NYSE: CLX) shares declined 1.13 percent to close at $92.64 a share Monday. The stock traded between $92.22 and $93.21 on volume of 1.37 million shares traded. Analysts at Goldman Sachs have recently downgraded the company’s rating to "sell" from "neutral". Shares of The Clorox Co. have gained approximately 25.0 percent year-to-date.
Find out more about The Clorox Co. including full access to the free equity report at:
www.RDInvesting.com/CLX
Ceres Inc. (NASDAQ: CERE) shares increased 2.40 percent to close at $1.71 a share Monday. The stock traded between $1.62 and $1.75 on volume of 257,747 shares traded. Analysts at Sidoti have recently downgraded the company’s rating to "neutral" from "buy". Shares of Ceres have fallen approximately 60.0 percent year-to-date.
Find out more about Ceres including full access to the free equity report at:
www.RDInvesting.com/CERE
Stryker Corporation (NYSE: SYK) shares increased 0.62 percent to close at $74.74 a share Monday. The stock traded between $74.54 and $75.50 on volume of 1.48 million shares traded. Analysts at Bernstein have recently upgraded the company’s rating to "outperform" from "market perform". Shares of Stryker have gained approximately 36.0 percent year-to-date.
Find out more about Stryker including full access to the free equity report at:
www.RDInvesting.com/SYK
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
info@rdinvesting.com